Catalyst Pharmaceuticals Inc Market Cap ($3.85 Billion)
Market Cap & Net Worth: Catalyst Pharmaceuticals Inc (CPRX)
Catalyst Pharmaceuticals Inc market cap. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has a market capitalization of $3.85 Billion ($3.85 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4114 globally and #1458 in its home market, demonstrating a 0.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Catalyst Pharmaceuticals Inc's stock price $31.49 by its total outstanding shares 122417458 (122.42 Million). Also see cash flow conversion of Catalyst Pharmaceuticals Inc for how efficiently the company converts equity into cash flow.
Catalyst Pharmaceuticals Inc Market Cap History (2015–2026)
Catalyst Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows growth from $299.92 Million to $3.85 Billion (22.97% CAGR). Check Catalyst Pharmaceuticals Inc (CPRX) stock price for real-time trading data and today's change.
Index Memberships
Catalyst Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.15% | #109 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.01% | #480 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.55 Trillion | 0.21% | #126 of 602 |
Weight: Catalyst Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Catalyst Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Catalyst Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CPRX net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.85x
Catalyst Pharmaceuticals Inc's market cap is 4.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
13.33x
Catalyst Pharmaceuticals Inc's market cap is 13.33 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $235.04 Million | $500.00K | -$34.00 Million | 470.08x | N/A |
| 2019 | $459.07 Million | $102.31 Million | $31.88 Million | 4.49x | 14.40x |
| 2020 | $408.87 Million | $119.07 Million | $74.98 Million | 3.43x | 5.45x |
| 2021 | $828.77 Million | $140.83 Million | $39.48 Million | 5.88x | 20.99x |
| 2022 | $2.28 Billion | $214.20 Million | $83.08 Million | 10.63x | 27.41x |
| 2023 | $2.06 Billion | $398.20 Million | $71.41 Million | 5.17x | 28.82x |
| 2024 | $2.55 Billion | $491.73 Million | $163.89 Million | 5.20x | 15.59x |
| 2025 | $2.86 Billion | $588.99 Million | $214.33 Million | 4.85x | 13.33x |
Competitor Companies of CPRX by Market Capitalization
Companies near Catalyst Pharmaceuticals Inc in the global market cap rankings as of November 5, 2026. Also see Catalyst Pharmaceuticals Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Catalyst Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Catalyst Pharmaceuticals Inc (2015–2026)
Market capitalization of Catalyst Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Catalyst Pharmaceuticals Inc's market cap moved from $299.92 Million to $ 3.85 Billion, with a yearly change of 22.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.85 Billion | +34.92% |
| 2025 | $2.86 Billion | +11.84% |
| 2024 | $2.55 Billion | +24.15% |
| 2023 | $2.06 Billion | -9.62% |
| 2022 | $2.28 Billion | +174.74% |
| 2021 | $828.77 Million | +102.69% |
| 2020 | $408.87 Million | -10.93% |
| 2019 | $459.07 Million | +95.31% |
| 2018 | $235.04 Million | -50.90% |
| 2017 | $478.65 Million | +272.38% |
| 2016 | $128.54 Million | -57.14% |
| 2015 | $299.92 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Catalyst Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.85 Billion USD |
| MoneyControl | $3.85 Billion USD |
| MarketWatch | $3.85 Billion USD |
| marketcap.company | $3.85 Billion USD |
| Reuters | $3.85 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more